Following these two breakthrough studies, Brown et al. conducted a phase I clinical trial in 65 patients with recurrent high-grade glioma (the majority of whom had recurrent GBM) by administering IL-13Rα2-targeted CAR-T cells through three different routes, including intratumoral (ICT), intraventricular (ICV), and dual ICT/ICV. The gene discussed is IL13RA2; the disease is glioblastoma.